» Articles » PMID: 8684533

Steroid Therapy During the Early Stage of Progressive IgA Nephropathy. A 10-year Follow-up Study

Overview
Journal Nephron
Publisher Karger
Specialty Nephrology
Date 1996 Jan 1
PMID 8684533
Citations 29
Authors
Affiliations
Soon will be listed here.
Abstract

This study was undertaken to clarify the effect of corticosteroids on the long-term clinical course of the early stage of progressive IgA nephropathy. The early stage of progressive IgA nephropathy was defined as having moderate proteinuria between 1 and 2 g/day, creatinine clearance values of 70 ml/min or more, and a histological severity score of 7 or more. The number of patients who fulfilled these three conditions during 12 years from 1972 and then were continuously followed up for 10 years or more in our renal unit was 46. Twenty of them received steroid treatment for an average period of 18 months, and the remaining 26 patients had no steroid treatment. The initial data of proteinuria, creatinine clearance values, frequency of hypertensive cases, and histological scores of 7 or more were not different between the two groups: 1.4 +/- 0.4 vs. 1.3 +/- 0.3 g/day, 85 +/- 14 vs. 88 +/- 13 ml/min, 25 vs. 38%, and 10.7 +/- 2.5 vs. 11.0 +/- 3.0, respectively. During the follow-up period of 10 years, the renal survival rate was significantly different between the two groups (100 vs. 84% 5 years after starting therapy and 80 vs. 34% 10 years later; p < 0.001). The final creatinine clearance values were significantly different between the two groups (54 +/- 35 vs. 20 +/- 29 ml/min; p < 0.005). On the other hand, the patient groups with mild histological changes or decreased renal function due to moderate proteinuria showed no significant differences in the final outcome. These results indicate that corticosteroids are beneficial in stabilizing the renal function for a long time during the early stage of progressive IgA nephropathy, although this study was not a randomized one.

Citing Articles

An Update on Current Therapeutic Options in IgA Nephropathy.

Lim R, Yeo S, Barratt J, Rizk D J Clin Med. 2024; 13(4).

PMID: 38398259 PMC: 10889409. DOI: 10.3390/jcm13040947.


Potential benefits and related treatment effects of calcineurin inhibitors combined with steroid for IgA nephropathy: a systematic review and meta-analysis.

Li Z, Yang Z, Ji M Int Urol Nephrol. 2023; 55(9):2227-2236.

PMID: 36856924 DOI: 10.1007/s11255-023-03524-1.


Corticosteroids and mycophenolic acid analogues in immunoglobulin A nephropathy with progressive decline in kidney function.

Huerta A, Merida E, Medina L, Fernandez M, Gutierrez E, Hernandez E Clin Kidney J. 2022; 15(4):771-777.

PMID: 35371455 PMC: 8967683. DOI: 10.1093/ckj/sfab244.


Meta-Analysis of the Effectiveness and Safety of Glucocorticoid for the Treatment of IgA Kidney Disease.

Sun J J Healthc Eng. 2022; 2022:5466331.

PMID: 35295167 PMC: 8920660. DOI: 10.1155/2022/5466331.


Immunosuppressive agents for treating IgA nephropathy.

Natale P, Palmer S, Ruospo M, Saglimbene V, Craig J, Vecchio M Cochrane Database Syst Rev. 2020; 3:CD003965.

PMID: 32162319 PMC: 7066485. DOI: 10.1002/14651858.CD003965.pub3.